This study will look at immunoglobulin (Ig) treatment in hospitalized chronic obstructive
lung disease (COPD) patients with frequent exacerbations.
This is a Phase II, pilot randomized double blind control study, meaning this study will help
assess if this research can be expanded to evaluate Ig treatment in patients with COPD. Ig
treatment is a sterile solution of human immunoglobulin proteins given intravenously (in the
vein). Immunoglobulins are part of the immune system and help the body fight infections.
Participants will be assigned to either receiving the Ig treatment or normal saline as a
control product every 4 weeks for 12 months.
Participants will continue on current standard therapy as determined by their treating
physician.
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
CSL Behring Grifols Biologicals Inc. Grifols Biologicals, LLC